U.S. FDA panel reviews Baxter immune therapy's long-term safety
July 30, 2014 at 16:30 PM EDT
Washington, July 30 (Reuters) - Advisors to the U.S. Food and Drug Administration will meet on Thursday to discuss the relative risks and benefits of Baxter International Inc's experimental treatment for certain hereditary disorders of the immune system.
